Neratinib was the most potent growth inhibitor in HER2+ breast cancer cell lines, and in the panel as a whole, while tucatinib was more effective than lapatinib in four of the five HER2+ breast cancer cell lines. This evidence concerns the gene ERBB2 and breast carcinoma.